Remove 2021 Remove Treatment Remove Trials
article thumbnail

Transforming cancer treatment for greatest impact

Drug Target Review

Could you provide insights into the driving factors behind exploring novel treatments for cancer types? Based on this rationale we selected skin cancer, triple-negative breast cancer, and head and neck cancers as our initial indications for our Phase 1 trials. What aspects prompted this research direction?

Treatment 105
article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options. 3D rendering of Antibody Drug Conjugate Molecules.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GSK showcases progress from the DREAMM clinical trial programme in multiple myeloma at the 2021 ASH Annual Meeting

The Pharma Data

GlaxoSmithKline plc moment blazoned 11 objectifications on Blenrep (belantamab mafodotin-blmf) will be presented at the forthcoming American Society of Hematology (ASH) Annual Meeting and Exposition, to be hosted in Atlanta, Georgia, US and nearly from 11-14 December 2021. Full list of belantamab mafodotin DREAMM trials and analyses.

article thumbnail

AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial

The Pharma Data

Trial met primary endpoint. The trial met the primary endpoint, with a cure of 600 mg of AZD7442 given by intramuscular (IM) injection reducing the threat of developing severe COVID-19 or death (from any cause) by 50 compared to placebo in rehabilitants who had been characteristic for seven days or lower.

Trials 52
article thumbnail

COVID-19 Master Protocol Trial Participants Should Be Randomized, FDA Says | 2021-05-17

The Pharma Data

The agency noted that master protocols can save drugmakers time and money in study startup and can accelerate drug development by evaluating multiple drugs at the same time and maximizing the amount of information gained during research, compared to stand-alone trials.

FDA 52
article thumbnail

Gilead Sciences Announces Second Quarter 2021 Financial Results

The Pharma Data

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We The series of promising pipeline updates included the data from the landmark ZUMA-7 study for the treatment of second-line large B-cell lymphoma.

Science 52
article thumbnail

AbbVie Reports Second-Quarter 2021 Financial Results

The Pharma Data

to $6.14; Raises 2021 Adjusted Diluted EPS Guidance Range from $12.37 Based upon the momentum of our business, we are raising our full year 2021 EPS guidance and believe AbbVie is very well positioned for the long term.” ” Second-Quarter Results. Worldwide net revenues were $13.959 billion, an increase of 33.9

FDA 52